Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Weiss

Showing results (131-140 of 152) with videos related to

Pageof 16
Sort By:
Breast Cancer Research and Treatment|January 23, 2019
Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at riskAnna Weiss, Samantha Grossmith, Danielle Cutts, et al.
JAMA|April 29, 2024
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized TrialWendy Y Chen, Karla V Ballman, Ann H Partridge, et al.
Cancer|March 23, 2023
Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohortsAnna Weiss, Olga Martínez-Sáez, Adrienne G Waks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2023
Financial Toxicity Monitoring in a Randomized Controlled Trial of Patient-Reported Outcomes During Cancer Treatment (Alliance AFT-39)Victoria S Blinder, Allison M Deal, Brenda Ginos, et al.
The British Journal of Surgery|September 18, 2025
BJS commission on the surgical management of the axilla in breast cancerMichael R Boland, Oreste D Gentilini, G Bruce Mann, et al.
Future Oncology (London, England)|October 12, 2021
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancerCiara C O'Sullivan, Karla V Ballman, Linda McCall, et al.
NPJ Breast Cancer|April 16, 2024
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancerStefania Morganti, Qingchun Jin, Julie Vincuilla, et al.
Annals of Surgical Oncology|November 23, 2025
Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS TrialAnna Weiss, Qingchun Jin, Nabihah Tayob, et al.
Teaching and Learning in Medicine|September 16, 2024
<i>How Might we Build an Equitable Future?</i> Design Justice, a Counternarrative to Dominant Approaches in Medical EducationHannah L Kakara Anderson, Xandro Xu, April Edwell, et al.
JCO Clinical Cancer Informatics|October 28, 2020
Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT TrialEthan Basch, Angela M Stover, Deborah Schrag, et al.
Pageof 16

Showing results (131-140 of 152) with videos related to

Sort By:
Pageof 16
Breast Cancer Research and Treatment|January 23, 2019
Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at riskAnna Weiss, Samantha Grossmith, Danielle Cutts, et al.
JAMA|April 29, 2024
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized TrialWendy Y Chen, Karla V Ballman, Ann H Partridge, et al.
Cancer|March 23, 2023
Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohortsAnna Weiss, Olga Martínez-Sáez, Adrienne G Waks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2023
Financial Toxicity Monitoring in a Randomized Controlled Trial of Patient-Reported Outcomes During Cancer Treatment (Alliance AFT-39)Victoria S Blinder, Allison M Deal, Brenda Ginos, et al.
The British Journal of Surgery|September 18, 2025
BJS commission on the surgical management of the axilla in breast cancerMichael R Boland, Oreste D Gentilini, G Bruce Mann, et al.
Future Oncology (London, England)|October 12, 2021
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancerCiara C O'Sullivan, Karla V Ballman, Linda McCall, et al.
NPJ Breast Cancer|April 16, 2024
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancerStefania Morganti, Qingchun Jin, Julie Vincuilla, et al.
Annals of Surgical Oncology|November 23, 2025
Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS TrialAnna Weiss, Qingchun Jin, Nabihah Tayob, et al.
Teaching and Learning in Medicine|September 16, 2024
<i>How Might we Build an Equitable Future?</i> Design Justice, a Counternarrative to Dominant Approaches in Medical EducationHannah L Kakara Anderson, Xandro Xu, April Edwell, et al.
JCO Clinical Cancer Informatics|October 28, 2020
Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT TrialEthan Basch, Angela M Stover, Deborah Schrag, et al.
Pageof 16